• September 21, 2020

EpimAb Biotherapeutics Announces FDA Clearance of its IND Application for EMB-02, a Bispecific Dual Checkpoint Inhibitor - Odessa American: Business

e-Edition Subscribe

EpimAb Biotherapeutics Announces FDA Clearance of its IND Application for EMB-02, a Bispecific Dual Checkpoint Inhibitor

Print
Font Size:
Default font size
Larger font size

Posted: Monday, September 14, 2020 11:00 pm | Updated: 11:32 pm, Mon Sep 14, 2020.

SHANGHAI--(BUSINESS WIRE)--Sep 15, 2020--

EpimAb Biotherapeutics, a clinical stage biotech company specializing in bispecific antibodies, today announced that it has received “STUDY MAY PROCEED” letter from the U.S. Food and Drug Administration (FDA) on an Investigational New Drug (IND) application for the Company’s second therapeutic development candidate, EMB-02. The application was submitted to the FDA to investigate the treatment of solid tumors with EpimAb’s novel bispecific antibody.

“The advancement of our second bispecific antibody into the clinic expands our clinical portfolio and also shows that our FIT-Ig® technology can generate a variety of clinical candidates,” commented Dr. Chengbin Wu, founder and CEO of EpimAb Biotherapeutics. “We expect to file additional applications in the near future for novel bispecific antibody programs being developed to treat patients suffering from serious cancer types. In 2021, we expect to have a total of three programs under investigation in clinical trials.”

EMB-02 is a bispecific antibody based on EpimAb’s proprietary FIT-Ig® (Fabs-In-Tandem Immunoglobulin) technology to generate bispecific molecules with superior properties. EMB-02 simultaneously targets two checkpoint proteins, PD-1 and LAG-3, and has shown strong anti-tumor activities in preclinical models resistant to standard anti-PD-1 monotherapies.

While EMB-02 is progressing towards the clinic, EpimAb continues to investigate EMB-01, its lead candidate, in a Phase I/II clinical study in both China and the U.S., and is generating several additional biologics, creating a proprietary pipeline based on its FIT-Ig® platform. These earlier-stage assets are focused on immuno-oncology approaches in areas of high unmet medical need in cancer.

About EpimAb Biotherapeutics, Inc.

EpimAb Biotherapeutics is a privately-owned biopharmaceutical R&D company with research and manufacturing facilities in Shanghai and Suzhou with a proprietary unique and efficient technology called FIT-Ig® (Fabs-In-Tandem Immunoglobulin) to generate bispecific molecules with antibody-like properties. With this platform EpimAb is creating a pipeline of its own novel bispecific antibody therapeutics focused around immuno-oncology and other areas of high value to patients. EpimAb is also committed to diversifying its pipeline through selective licensing of its platform and pipeline assets to partners worldwide. For further information, please visit www.epimab.com

View source version on businesswire.com:https://www.businesswire.com/news/home/20200914005947/en/

CONTACT: EpimAb Biotherapeutics

In the U.S.:

Dr. Stephan Lensky, COO/CBO

Direct: +1 978-870-6276

Stephan.lensky@epimab.comIn China:

Dr. Jason Tang,BD Director

Direct: +86-21- 61951000

E-Mail:yesheng.tang@epimab.comMedia Inquiries

MacDougall

Amanda Houlihan

+1 781-235-3060

epimab@macbiocom.com

KEYWORD: CHINA ASIA PACIFIC

INDUSTRY KEYWORD: ONCOLOGY HEALTH FDA GENERAL HEALTH CLINICAL TRIALS PHARMACEUTICAL BIOTECHNOLOGY

SOURCE: EpimAb Biotherapeutics, Inc.

Copyright Business Wire 2020.

PUB: 09/15/2020 12:00 AM/DISC: 09/15/2020 12:00 AM

http://www.businesswire.com/news/home/20200914005947/en

© 2020 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

Odessa, TX

Current Conditions

Clear
73°
Humidity: 50%
Winds: ESE at 12mph
Feels Like: 73°

Your Extended Forecast

Tomorrow

weather
High 84°/Low 54°
Clear. Lows overnight in the mid 50s.

tuesday

weather
High 85°/Low 58°
Sunshine. Highs in the mid 80s and lows in the upper 50s.

wednesday

weather
High 85°/Low 59°
Partly cloudy. Highs in the mid 80s and lows in the upper 50s.
Online Features

Pet Central

pets

Having a pet is a lot of responsibility, and we’ll help by giving you lots of tips and tricks! More >>

Fitness

Fitness

Our fitness articles will help teach you how to work out with gym- and home-based exercises. More >>

Crosswords

Crosswords

Enjoy the crosswords challenge in our free daily puzzles, from the harder Sunday crossword to the quicker daily. More >>

Sudoku

Sudoku

Every Sudoku has a unique solution that can be reached logically. Enter numbers into the blank spaces so that each row, column and 3x3 box contains the numbers 1 to 9. More >>




  • ALL-ACCESS: Subscribe to our e-edition and premium website at myoaoa.com.
    You can read your daily newspaper without taking a walk to the driveway.
    Look back at yesterday's newspaper, or issues from months ago with our archive feature.
    Call circulation at 432-337-7314 to sign up today.